Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For older LBCL patients, Axi-Cel exhibits durable responses and extends overall survival.

2.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

3.

Survival is extended by a new treatment option for metastatic colorectal cancer.

4.

Three out of ten breast cancers detected between screenings, study finds

5.

Basal stem-like cells identified as origin of small cell lung cancer in lab models


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot